Get the Stockscreener App
8.71
11.81%
0.92
After Hours:
8.48
-0.23
-2.64%
Immunitybio Inc stock is traded at $8.71, with a volume of 40.97M.
It is up +11.81% in the last 24 hours and up +9.97% over the past month.
ImmunityBio Inc is a biotechnology company focused on developing and commercializing next-generation immunotherapies designed to activate the patient's immune system and provide durable protection against cancer and infectious diseases. Its approach harnesses both the adaptive and innate immune systems with the Cancer BioShield platform. The platform is built around the proprietary IL-15 superagonist ANKTIVA (nogapendekin alfa inbakicept) and is supported by a portfolio that includes adenovirus-vectored vaccines, NK-cell therapies, and additional immunomodulators. The company operates in the United States and Europe, with the majority of its revenue coming from the United States.
See More
Previous Close:
$7.79
Open:
$7.74
24h Volume:
40.97M
Relative Volume:
2.59
Market Cap:
$9.12B
Revenue:
$140.98M
Net Income/Loss:
$-854.60M
P/E Ratio:
-10.20
EPS:
-0.854
Net Cash Flow:
$-299.31M
1W Performance:
+18.34%
1M Performance:
+9.97%
6M Performance:
+307.01%
1Y Performance:
+212.19%
1-Day Range:
$7.67
$8.85
1-Week Range:
$7.00
$8.85
52-Week Range:
$1.95
$12.43
Immunitybio Inc Stock (IBRX) Company Profile
Name
Immunitybio Inc
Sector
Industry
Phone
(844) 696-5235
Address
3530 JOHN HOPKINS COURT, SAN DIEGO
Compare IBRX vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IBRX
Immunitybio Inc
|
8.71 | 8.16B | 140.98M | -854.60M | -299.31M | -0.854 |
VRTX
Vertex Pharmaceuticals Inc
|
491.34 | 121.87B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
632.90 | 65.01B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
887.18 | 55.26B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
291.37 | 39.14B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
182.08 | 37.88B | 742.00K | -1.37B | -1.07B | -7.0731 |
Immunitybio Inc Stock (IBRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-12-26 | Resumed | BTIG Research | Buy |
| May-20-25 | Upgrade | Piper Sandler | Neutral → Overweight |
| Mar-06-25 | Initiated | H.C. Wainwright | Buy |
| Jan-10-25 | Initiated | BTIG Research | Buy |
| May-12-23 | Downgrade | Piper Sandler | Overweight → Neutral |
| Aug-03-22 | Initiated | Jefferies | Buy |
View All
Immunitybio Inc Stock (IBRX) Latest News
Director Barry Simon Sells 25,000 Shares of ImmunityBio Inc (IBR - GuruFocus
Form 4 Immunitybio Inc For: 26 June By Investing.com - Investing.com Canada
ImmunityBio (NASDAQ: IBRX) director sells 25,000 shares under 10b5-1 plan - Stock Titan
ImmunityBio director Simon Barry J. sells $196,907 of common stock By Investing.com - Investing.com Nigeria
Price to sales forward of ImmunityBio, Inc. – NASDAQ:IBRX - TradingView
ImmunityBio (NASDAQ:IBRX) rises as Russell index rebalancing and high multiple draw buyers - TechStock²
Price to earnings forward of ImmunityBio Inc – SWB:26CA - TradingView
IBRX Stock Climbs As ANKTIVA Data Spotlight Draws Traders - StocksToTrade
IBRX Stock Climbs Overnight: ImmunityBio Declares ‘All Systems Go’ For Dunkirk Anktiva Manufacturing Push - Stocktwits
ImmunityBio, Inc. (IMMP) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
IBRX Stock Price Prediction 2025-2026 | Immunitybio Inc Forecast - 24/7 Wall St.
ImmunityBio reports progress on bladder cancer filing, shares trade quietly on NASDAQ - Ad-hoc-news.de
IBRX Founder’s ‘Congrats’ To GSK Sparks Debate After FDA Fast Drug Approvals — Retail Slams Big Pharma Bias Over Anktiva - Stocktwits
Price to book forward of ImmunityBio, Inc. – NASDAQ:IBRX - TradingView
ImmunityBio Founder Pushes Back After FDA Warning Letter Over Anktiva Claims — Says Ad 'Never Aired At All' - Stocktwits
Bronstein, Gewirtz & Grossman, LLC Encourages ImmunityBio, Inc. (IMMP) Shareholders to Inquire about Securities Investigation - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Is Investigating ImmunityBio, Inc. (IMMP) And Encourages Shareholders to Connect - ACCESS Newswire
Jim Cramer Says “Let ImmunityBio Be Your Speculation” to a Caller - Insider Monkey
IBRX Vs IOVA: Which Cancer Immunotherapy Stock Has Bigger Breakout Ahead? - Stocktwits
IBRX Stock In Spotlight As FDA Scrutiny Prompts ImmunityBio To Withdraw Content, Tighten Oversight - Stocktwits
IBRX Stock Rises Premarket: Anktiva Moves Into Pre-Surgery Pancreatic Cancer Combo Trial With Bristol Myers Drug - Stocktwits
IBRX Stock Rally Not Over Yet? Chairman Says Trump Diplomacy Led To ‘Amazing Results’ For Cancer Drug - Stocktwits
symbol__ Stock Quote Price and Forecast - CNN
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against ImmunityBio, Inc. (IMMP) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire
ImmunityBio, Inc. (IMMP) Investigation: Bronstein, Gewirtz & Gros - The National Law Review
ImmunityBio, Inc. (NASDAQ:IBRX): Are Analysts Optimistic? - Moomoo
Bronstein, Gewirtz & Grossman, LLC Is Investigating ImmunityBio, Inc. (IMMP) And Encourages Investors to Connect - ACCESS Newswire
IBRX stock eyes best week since February: Founder highlights new Anktiva-NK cell therapy study - MSN
ImmunityBio | 4: Statement of changes in beneficial ownership of securities-Director Selecky Christobel - Moomoo
ImmunityBio (IBRX): One of the Best Performing Growth Stocks So Far in 2026 - Insider Monkey
ImmunityBio (IBRX) director awarded 65,600 stock options at $7.25 strike - Stock Titan
ImmunityBio (IBRX) director Wesley Clark receives 65,600 stock options at $7.25 strike - Stock Titan
ImmunityBio (IBRX) director granted 65,600 stock options at $7.25 strike - Stock Titan
Director at ImmunityBio (NASDAQ: IBRX) awarded 65,600 options - Stock Titan
ImmunityBio (IBRX) re-elects full board, ratifies Deloitte as 2026 auditor - Stock Titan
Bronstein, Gewirtz & Grossman, LLC Encourages ImmunityBio, Inc - The National Law Review
2026-06-09 | Bronstein, Gewirtz & Grossman, LLC Encourages ImmunityBio, Inc. (IMMP) Stockholders to Inquire about Securities Investigation | NDAQ:IMMP | Press Release - Stockhouse
IBRX Stock Set To Snap 2 Weeks In Red: Anktiva Joins Global Blockbusters On Macau Drug List - Stocktwits
FDA to Review Expanded Use of Cancer Drug - Los Angeles Business Journal
IBRX Stock Eyes Green Open Ahead Of Earnings — What Happened With Anktiva Over The Weekend - Stocktwits
IBRX Stock Still A Buy After Worst Day In Over A Year? Why This Analyst Is Shrugging Off FDA Warning Letter - Stocktwits
ImmunityBio, Inc. (IMMP) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
ImmunityBio, Inc.: Shareholders Board Members Managers and Company Profile | US45256X1037 - marketscreener.com
ImmunityBio Inc Cash Flow – XETR:26CA - TradingView
ImmunityBio director Simon Barry J. sells $165,305 in stock - Investing.com UK
Director Barry Simon Sells 23,033 Shares of ImmunityBio Inc (IBR - GuruFocus
Immunitybio earnings loom amid Anktiva growth, FDA scrutiny - Investing.com
ImmunityBio Inc. (IBRX): One of the Most Shorted Mid-Cap Stocks to Buy Now - Yahoo Finance
ImmunityBio director Simon Barry J. sells $165,305 in stock By Investing.com - Investing.com India
Immunitybio Inc Stock (IBRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.36%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):